RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE)
Sponsor: Ayala Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAT7686
U.S. Govt. ID: NCT04871282
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study drug and how your body processes the drug. The study drug works by stopping a chemical pathway in the cells that allows desmoid tumors to grow. It is hoped that by stopping this pathway the study drug will stop desmoid tumor cells from growing and may cause them to shrink. The study drug is a capsule which is taken by mouth. Part A of the study is an open-label study, which means both you and your study doctor will know that you are taking the study drug.
Prabhjot Mundi, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with a desmoid tumor? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator